An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00135330 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of exenatide and rosiglitazone on blood sugar control in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 137 people

Who can join Ages 18–75 · all sexes

Timeline Started 2005-10 · est. completion 2008-07

Where 19 sites · United States

What this study is testing ClinicalTrials.gov NCT00135330 ↗

Description as written by the study sponsor.

This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.

Treatments tested

exenatide also known as Byetta Drug

subcutaneous injection, 5mcg or 10mcg, twice a day
rosiglitazone also known as Avandia Drug

oral tablet, 2mg or 4mg, twice a day

Main thing measured	Change in ASIiAUC During a Hyperglycemic Clamp Test.
Sponsor	AstraZeneca
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00135330 ↗